Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Avid Radiopharmaceuticals
Age
Any age
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Male subjects consented and currently enrolled in the Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests (DETECT) or the Long-Term Consequences of Repetitive Brain Injury in Athletes study protocols
Can tolerate up to two PET imaging sessions
Have the ability to provide informed consent for study procedures
You may not be if
Claustrophobia
Current clinically significant cardiovascular disease or clinically significant abnormalities on screening ECG
History of risk factors for Torsades de Pointes or are taking drugs known to cause QT-prolongation
Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer that the investigator believes would affect study participation or scan results
Have had a non-study related radiopharmaceutical imaging or treatment within 7 days prior to study PET imaging sessions
Clareo Health | 18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
